Cargando…

Meta-Analysis of Sulfonylurea Therapy on Long-Term Risk of Mortality and Cardiovascular Events Compared to Other Oral Glucose-Lowering Treatments

INTRODUCTION: Among the most pressing clinical decisions in type 2 diabetes treatments are which drugs should be used after metformin is no longer sufficient, and whether sulfonylureas (SUs) should remain as a suitable second-line treatment. In this article we summarize current evidence on the long-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Powell, W. Ryan, Christiansen, Cindy L., Miller, Donald R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6064594/ https://www.ncbi.nlm.nih.gov/pubmed/29808360 http://dx.doi.org/10.1007/s13300-018-0443-z

Ejemplares similares

Controversy about the relationship between sulfonylurea use and cardiovascular events and mortality
por: Shimoda, Masashi, et al.
Publicado: (2016)

Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose-lowering Therapies for Three Acute Outcomes
por: Gamble, John-Michael, et al.
Publicado: (2018)

Factors influencing the durability of the glucose‐lowering effect of sitagliptin combined with a sulfonylurea
por: Kubota, Akira, et al.
Publicado: (2014)

Novel oral glucose‐lowering drugs are associated with lower risk of all‐cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes
por: Nyström, Thomas, et al.
Publicado: (2017)

Glucose-dependent and Glucose-sensitizing Insulinotropic Effect of Nateglinide: Comparison to Sulfonylureas and Repaglinide
por: Hu, Shiling, et al.
Publicado: (2001)

Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study
por: Douros, Antonios, et al.
Publicado: (2018)

Sulfonylureas: Asset or liability?
por: Lakhani, Om J., et al.
Publicado: (2015)

Sulfonylureas at the Glomerular Battlefield
por: Kalra, Sanjay, et al.
Publicado: (2018)

Effect of Sulfonylureas Administered Centrally on the Blood Glucose Level in Immobilization Stress Model
por: Sharma, Naveen, et al.
Publicado: (2015)

aThe characteristics of glucose metabolism in the sulfonylurea receptor 1 knockout rat model
por: Zhou, Xiaojun, et al.
Publicado: (2019)

Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes
por: Xie, Yan, et al.
Publicado: (2021)

Reduction of Sulfonylurea with the Initiation of Basal Insulin in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Undergoing Long-Term Sulfonylurea-Based Treatment
por: Yang, Yeoree, et al.
Publicado: (2016)

Effects of Sulfonylureas on Peroxisome Proliferator-Activated Receptor γ Activity and on Glucose Uptake by Thiazolidinediones
por: Lee, Kyeong Won, et al.
Publicado: (2011)

Deletion of Sulfonylurea Receptor 2 in the Adult Myocardium Enhances Cardiac Glucose Uptake and Is Cardioprotective
por: Aubert, Gregory, et al.
Publicado: (2019)

Response of circulating metabolites to an oral glucose challenge and risk of cardiovascular disease and mortality in the community
por: Gonzalez Izundegui, Daniel, et al.
Publicado: (2022)

Long‐term follow‐up of children with in utero exposure to sulfonylurea medications
por: Rodenstein, Marissa S., et al.
Publicado: (2021)

Is the Combination of Sulfonylureas and Metformin Associated With an Increased Risk of Cardiovascular Disease or All-Cause Mortality?: A meta-analysis of observational studies
por: Rao, Ajay D., et al.
Publicado: (2008)

Sulfonylurea action re‐revisited
por: Seino, Susumu, et al.
Publicado: (2010)

Sulfonylureas and their use in clinical practice
por: Sola, Daniele, et al.
Publicado: (2015)

The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials
por: Varvaki Rados, Dimitris, et al.
Publicado: (2016)

Consensus Recommendations on Sulfonylurea and Sulfonylurea Combinations in the Management of Type 2 Diabetes Mellitus – International Task Force
por: Kalra, Sanjay, et al.
Publicado: (2018)

Cardiovascular Safety in Type 2 Diabetes With Sulfonylureas as Second-line Drugs: A Nationwide Population-Based Comparative Safety Study
por: Wang, Huan, et al.
Publicado: (2023)

Glucose-dependent insulinotropic peptide and risk of cardiovascular events and mortality: a prospective study
por: Jujić, Amra, et al.
Publicado: (2020)

Association between use of warfarin with common sulfonylureas and serious hypoglycemic events: retrospective cohort analysis
por: Romley, John A, et al.
Publicado: (2015)

Sulfonylureas: Assets in the past, present and future
por: Kalra, Sanjay, et al.
Publicado: (2015)

Sulfonylureas: Scoring beyond START STUDY
por: Shaikh, Altamash
Publicado: (2017)

Sulfonylurea and neuroprotection: The bright side of the moon
por: Hussien, Nawar R., et al.
Publicado: (2018)

The Place of Sulfonylureas in Guidelines: Why Are There Differences?
por: Amod, Aslam
Publicado: (2020)

Latest Evidence on Sulfonylureas: What’s New?
por: Leiter, Lawrence A.
Publicado: (2020)

Role of Octreotide in Sulfonylurea-Induced Hypoglycemia
por: Zafar, Sheema, et al.
Publicado: (2021)

Commentary on “Consensus Recommendations on Sulfonylurea and Sulfonylurea Combinations in the Management of Type 2 Diabetes Mellitus: International Task Force”
por: Singh, S. K.
Publicado: (2018)

Correction: The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials
por: Rados, Dimitris Varvaki, et al.
Publicado: (2016)

Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors
por: Scheen, André J.
Publicado: (2018)

Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study
por: Wong, Carlos K. H., et al.
Publicado: (2019)

Withdrawal of sulfonylureas from patients with type 2 diabetes receiving long-term sulfonylurea and insulin combination therapy results in deterioration of glycemic control: a randomized controlled trial
por: Srivanichakorn, Weerachai, et al.
Publicado: (2015)

Intensive Glucose-Lowering Therapy Reduces Cardiovascular Disease Events in Veterans Affairs Diabetes Trial Participants With Lower Calcified Coronary Atherosclerosis
por: Reaven, Peter D., et al.
Publicado: (2009)

SAT-139 Clinical Impact of Oral Semaglutide Compared with Sitagliptin in T2D on Metformin ± Sulfonylurea: The Pioneer 3 Trial
por: Rosenstock, Julio, et al.
Publicado: (2019)

Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials
por: Boussageon, Rémy, et al.
Publicado: (2011)

Impact of sarcopenia on long-term mortality and cardiovascular events in patients undergoing hemodialysis
por: Kim, Jwa-Kyung, et al.
Publicado: (2019)

Long‐Term Effects of Unprovoked Venous Thromboembolism on Mortality and Major Cardiovascular Events
por: Chang, Wei‐Ting, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_cujprrsbgfo5b0q28bn0ovcui6